• Ipsen Pharmaceuticals in various patent prosecution and Orange Book patent strategy matters relating to Tazverik® (tazemetostat).
    • Nimbus Therapeutics in various patent prosecution and IP diligence matters culminating in Takeda’s acquisition of NDI-034858 (TAK-279; Zasocitinib), its small molecule TKY2 inhibitor, for US$6 billion in cash and commercial milestone payments.
    • X4 Pharmaceuticals in various patent prosecution and counseling matters since its inception in 2015; for example, in maximizing patent and regulatory exclusivities for its CXCR4 inhibitor, mavorixafor (X4P-001), which is a rescued drug currently in Phase 3 clinical trials for the orphan disease WHIM syndrome.
    • Royalty Pharma in various validity and LOE analyses, including in relation to its US$827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta® (eltrombopag).
    • Pharnext in U.S. patent prosecution and counseling matters relating to PXT3003, a combination of three known small molecule drugs that is in Phase 3 clinical trials for a rare genetic disease.
    • 2020 Pro Bono High Honor Roll, Supreme Judicial Court of Massachusetts (awarded to individual attorneys who complete at least 100 hours of pro bono service during the previous year)
    • American Bar Association
    • American Intellectual Property Association